- Previous Close
0.0700 - Open
0.0720 - Bid 0.0700 x --
- Ask 0.0735 x --
- Day's Range
0.0695 - 0.0755 - 52 Week Range
0.0650 - 5.6400 - Volume
663,322 - Avg. Volume
629,182 - Market Cap (intraday)
16.433M - Beta (5Y Monthly) --
- PE Ratio (TTM)
0.15 - EPS (TTM)
0.4800 - Earnings Date Feb 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.26
Scandion Oncology A/S, a clinical-stage biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase II clinical trial for the treatment of colorectal cancer; and in Phase I clinical trial for treating pancreatic cancer, as well as in preclinical studies for other cancer indications. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark.
www.scandiononcology.comRecent News: SCOL.ST
View MorePerformance Overview: SCOL.ST
Trailing total returns as of 11/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SCOL.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SCOL.ST
View MoreValuation Measures
Market Cap
16.43M
Enterprise Value
-6.25M
Trailing P/E
0.15
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.45
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-61.15%
Return on Equity (ttm)
-98.68%
Revenue (ttm)
-494k
Net Income Avi to Common (ttm)
-32.47M
Diluted EPS (ttm)
0.4800
Balance Sheet and Cash Flow
Total Cash (mrq)
14.81M
Total Debt/Equity (mrq)
0.69%
Levered Free Cash Flow (ttm)
-26.94M